Company intelligence / Profile preview

PuraMed BioScience

Schofield, Wisconsin, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

PuraMed BioScience developed non-prescription remedies such as LipiGesic M and MigraPure gel targeting migraine relief. Some clinical study results were anticipated around the time of product launches circa early-mid 2010s, but no recent peer-reviewed data or regulatory filings are available. The company also explored cannabinoid-based medicines as of ~2014. No evidence of ongoing late-stage clinical trials or new approvals since then.

Therapeutic areas: Neurology
Modalities: Small moleculeHerbal/plant-based therapyHomeopathic formulation
Industry: Food & Nutrition

Drug pipeline

3 assets

LipiGesic M

Commercial

Indications: Migraine

2 more assets in the full pipeline.

Request access →

Partnerships

marketing partnership with Lone Wolf Inc./LWI for social media outreach in the past

Beyond the preview

Go deeper on PuraMed BioScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PuraMed BioScience.

Explore the full profile